Sarilumab, another IL-6 receptor antagonist, happens to be FDA-approved for arthritis rheumatoid. Sarilumab has been found in open-label cohort studies for the management of severe COVID-19 and has undergone analysis in unpublished RCTs for average and severe COVID-19 [92-96]. Systematic review and horizon scan of the literature identified 2030 personal references of which 48 enlightened the evidence base for these tips . Characteristics of the included studies are available in the supplementary materials. For several interventions, no direct evidence was available apart from case information or mechanistic considerations.